• Company
• A single tech export brings in 11 times the annual revenue
• by Chon, Seung-Hyun Jan 13, 2022 06:05am

• Policy
• NHRC issues ‘expedited listing of Kymriah’ opinion to MOHW
• by Lee, Jeong-Hwan Jan 13, 2022 06:05am

• Company
• Viatris & J&J hired female executives
• by Eo, Yun-Ho Jan 12, 2022 06:05am

• Company
• Keytruda-Renvima has been approved as the primary treatment
• by Jan 12, 2022 06:05am

• Opinion
• [Reporter’s View] Can companies get EUAs as they promised?
• by Lee, Tak-Sun Jan 12, 2022 06:04am

• Company
• Reducing # of sales positions of pharmaceutical companies
• by Moon, sung-ho Jan 12, 2022 06:04am

• Product
• The gov is pushing to supply COVID-19 PO tx with pharmacies
• by Kang, Shin-Kook Jan 12, 2022 06:04am

• Company
• Pharmaceutical bio jobs to be reorganized
• by Chon, Seung-Hyun Jan 12, 2022 06:04am

• Company
• Soliris at risk of price cuts amid increasing PA rejections
• by Moon, sung-ho Jan 12, 2022 06:04am

• Company
• Ultra-high-priced ‘Kymriah’ is up for DREC deliberations
• by Eo, Yun-Ho Jan 11, 2022 06:29am